Table 3

Association of phenotypes and genotypes with cessation due to side effects

SNP

Phenotype/Genotype

Proportion ceased due to side effects (%)

Hazard Ratio (95% Confidence Interval), P-value*


CYP2C19 (CYP2C19*2 (rs4244285), CYP2C19*17 (rs12248560))

Poor/Intermediate metabolizers

8/15 (53.3%)

0.432 (0.237 to 0.790), P = 0.006†


Extensive metabolizers

18/39 (46.2%)


Ultra-rapid metabolizers

5/21 (23.8%)


ABCG2 421C>A (rs2231142)

AC

6/14 (42.9%)

1.297 (0.527 to 3.194), P = 0.572


CC

27/64 (42.2%)


CYP1A2*1F (rs762551)

AA

16/38 (42.1%)

1.021 (0.508 to 2.050), P = 0.954


AC +CC

17/40 (42.5%)


DHODH 19C>A (rs3213422)

AA

9/20 (45%)

1.002 (0.610 to 1.648), P = 0.993†


AC

16/39 (41.0%)


CC

8/19 (42.1%)


All genotypes are in Hardy-Weinberg equilibrium. *after adjustment for dose, continuing triple therapy and positive rheumatoid factor. † Hazard Ratio and P-value represent a linear test for trend. The Hazard Ratio refers to the hazard associated with each incremental change in phenotype.

Wiese et al. Arthritis Research & Therapy 2012 14:R163   doi:10.1186/ar3911

Open Data